News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
754,406 Results
Type
Article (45387)
Company Profile (313)
Press Release (708686)
Multimedia
Podcasts (132)
Webinars (22)
Section
Business (213019)
Career Advice (2221)
Deals (37085)
Drug Delivery (143)
Drug Development (83945)
Employer Resources (178)
FDA (16969)
Job Trends (15598)
News (360565)
Policy (34514)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2671)
Accelerated approval (43)
Adcomms (27)
Allergies (171)
Alliances (51827)
ALS (204)
Alzheimer's disease (1791)
Antibody-drug conjugate (ADC) (432)
Approvals (17305)
Artificial intelligence (650)
Autoimmune disease (250)
Automation (53)
Bankruptcy (377)
Best Places to Work (11812)
BIOSECURE Act (21)
Biosimilars (219)
Biotechnology (188)
Bladder cancer (183)
Brain cancer (72)
Breast cancer (715)
Cancer (5640)
Cardiovascular disease (469)
Career advice (1890)
Career pathing (43)
CAR-T (314)
CDC (60)
Celiac Disease (2)
Cell therapy (838)
Cervical cancer (44)
Clinical research (72355)
Collaboration (2048)
Company closure (5)
Compensation (1325)
Complete response letters (85)
COVID-19 (2832)
CRISPR (106)
C-suite (1082)
Cystic fibrosis (154)
Data (7435)
Decentralized trials (3)
Denatured (39)
Depression (161)
Dermatology (70)
Diabetes (563)
Diagnostics (6998)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (46)
Drug discovery (318)
Drug pricing (217)
Drug shortages (35)
Duchenne muscular dystrophy (277)
Earnings (93943)
Editorial (70)
Employer branding (21)
Employer resources (157)
Events (122688)
Executive appointments (1093)
FDA (20555)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (33)
Funding (1686)
Gene editing (223)
Generative AI (57)
Gene therapy (695)
GLP-1 (1088)
Government (4949)
Grass and pollen (7)
Guidances (402)
Healthcare (19318)
HIV (76)
Huntington's disease (53)
IgA nephropathy (95)
Immunology and inflammation (291)
Immuno-oncology (88)
Indications (167)
Infectious disease (3166)
Inflammatory bowel disease (214)
Inflation Reduction Act (14)
Influenza (135)
Intellectual property (284)
Interviews (348)
IPO (17039)
IRA (57)
Job creations (4103)
Job search strategy (1577)
JPM (65)
Kidney cancer (18)
Labor market (94)
Layoffs (594)
Leadership (38)
Legal (8531)
Liver cancer (99)
Longevity (31)
Lung cancer (752)
Lymphoma (418)
Machine learning (57)
Management (60)
Manufacturing (1002)
MASH (187)
Medical device (14055)
Medtech (14140)
Mergers & acquisitions (21242)
Metabolic disorders (1479)
mRNA (201)
Multiple sclerosis (181)
NASH (18)
Neurodegenerative disease (399)
Neuropsychiatric disorders (105)
Neuroscience (3266)
Neurotech (1)
NextGen: Class of 2026 (6694)
Non-profit (4610)
Now hiring (74)
Obesity (702)
Opinion (315)
Ovarian cancer (203)
Pain (258)
Pancreatic cancer (278)
Parkinson's disease (354)
Partnered (34)
Patents (578)
Patient recruitment (628)
Peanut (64)
People (62053)
Pharmaceutical (85)
Pharmacy benefit managers (35)
Phase 1 (22462)
Phase 2 (31807)
Phase 3 (23828)
Pipeline (7674)
Policy (329)
Postmarket research (2697)
Preclinical (9577)
Press Release (68)
Prostate cancer (286)
Psychedelics (55)
Radiopharmaceuticals (326)
Rare diseases (1056)
Real estate (6354)
Recruiting (73)
Regulatory (26235)
Reports (55)
Research institute (2487)
Resumes & cover letters (372)
Rett syndrome (34)
RNA editing (21)
RSV (88)
Schizophrenia (180)
Series A (281)
Series B (211)
Service/supplier (11)
Sickle cell disease (111)
Special edition (27)
Spinal muscular atrophy (168)
Sponsored (47)
Startups (3809)
State (2)
Stomach cancer (19)
Supply chain (129)
Tariffs (100)
The Weekly (91)
Vaccines (1114)
Venture capital (104)
Weight loss (461)
Women's health (117)
Worklife (20)
Date
Today (196)
Last 7 days (774)
Last 30 days (2817)
Last 365 days (31025)
2026 (9741)
2025 (30838)
2024 (35950)
2023 (40831)
2022 (52031)
2021 (56532)
2020 (55059)
2019 (47718)
2018 (36035)
2017 (33416)
2016 (33004)
2015 (38942)
2014 (32876)
2013 (27985)
2012 (30102)
2011 (30818)
2010 (28857)
Location
Africa (824)
Alabama (91)
Alaska (7)
Arizona (347)
Arkansas (16)
Asia (43049)
Australia (6939)
California (12701)
Canada (3646)
China (1318)
Colorado (552)
Connecticut (553)
Delaware (384)
Europe (92847)
Florida (1898)
Georgia (406)
Hawaii (3)
Idaho (62)
Illinois (1024)
India (90)
Indiana (588)
Iowa (23)
Japan (524)
Kansas (130)
Kentucky (47)
Louisiana (41)
Maine (75)
Maryland (1523)
Massachusetts (9119)
Michigan (353)
Minnesota (694)
Mississippi (6)
Missouri (142)
Montana (33)
Nebraska (29)
Nevada (138)
New Hampshire (86)
New Jersey (3380)
New Mexico (29)
New York (3350)
North Carolina (1633)
North Dakota (8)
Northern California (6302)
Ohio (381)
Oklahoma (24)
Oregon (47)
Pennsylvania (2567)
Puerto Rico (28)
Rhode Island (50)
South America (1201)
South Carolina (84)
South Dakota (2)
Southern California (5004)
Tennessee (203)
Texas (2004)
United States (45080)
Utah (381)
Vermont (1)
Virginia (314)
Washington D.C. (82)
Washington State (1019)
West Virginia (4)
Wisconsin (128)
Wyoming (2)
754,406 Results for "fresenius kabi pharmaceuticals holding inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CMS Grants Fresenius Kabi COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg)
April 10, 2026
·
13 min read
Press Releases
Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement
January 15, 2026
·
5 min read
Press Releases
Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara®
January 6, 2026
·
12 min read
Press Releases
Fresenius Kabi and Phlow Corp. Announce First-Ever, End-to-End, U.S. Manufacturing Collaboration for Epinephrine Injection, USP
February 10, 2026
·
7 min read
Press Releases
Fresenius Kabi Introduces First-Ever Rocuronium Bromide Injection Stable at Room Temperature
December 19, 2025
·
5 min read
Press Releases
FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilars Conexxence® and Bomyntra® (denosumab-bnht)
October 29, 2025
·
4 min read
Press Releases
Fresenius Kabi Introduces Dalbavancin for Injection (for single-dose regimen use only)
November 24, 2025
·
5 min read
Press Releases
Fresenius Kabi’s Adaptive Nomogram used on Aurora Xi Plasmapheresis System Now Operating Nationwide at BioLife Plasma Centers
November 12, 2025
·
3 min read
Press Releases
Fresenius Kabi Receives Two Major Awards for Supply and Service Excellence from Vizient®
September 25, 2025
·
3 min read
Press Releases
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Conexxence® and Bomyntra® (denosumab-bnht)
September 29, 2025
·
5 min read
1 of 75,441
Next
